Skip to Content

New Drug Approvals Archive - August 2012

August 2012

Zaltrap (ziv-aflibercept) Injection

Date of Approval: August 3, 2012
Company: Sanofi and Regeneron Pharmaceuticals, Inc.
Treatment for: Colorectal Cancer

Zaltrap (ziv-aflibercept) is an angiogenesis inhibitor for the combination treatment of patients with metastatic colorectal cancer.

Read more: Zaltrap (ziv-aflibercept) FDA Approval History

Marqibo (vincristine sulfate liposomes) Injection - formerly Onco TCS

Date of Approval: August 9, 2012
Company: Talon Therapeutics Inc.
Treatment for: Acute Lymphoblastic Leukemia

Marqibo (vincristine sulfate liposome injection) is a vinca alkaloid indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Read more: Marqibo (vincristine sulfate liposomes) FDA Approval History

Lucentis (ranibizumab)

New Indication Approved: August 10, 2012
Treatment for: Macular Degeneration; Macular Edema; Diabetic Macular Edema; Diabetic Retinopathy; Myopic Choroidal Neovascularization

Read more: Lucentis (ranibizumab) FDA Approval History

Auvi-Q (epinephrine) Injection

Date of Approval: August 10, 2012
Company: Sanofi
Treatment for: Anaphylaxis, Allergic Reaction

Auvi-Q (epinephrine injection) is a voice-guided epinephrine auto-injector for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis.

Read more: Auvi-Q (epinephrine) FDA Approval History

Stribild (cobicistat, elvitegravir, emtricitabine and tenofovir) Tablets

Date of Approval: August 27, 2012
Company: Gilead Sciences, Inc.
Treatment for: HIV Infection

Stribild (cobicistat, elvitegravir, emtricitabine and tenofovir) is a complete once-daily single tablet regimen for HIV-1 infection for treatment-naïve adults.

Read more: Stribild (cobicistat, elvitegravir, emtricitabine and tenofovir) FDA Approval History

Granix (tbo-filgrastim) Injection

Date of Approval: August 29, 2012
Company: Teva Pharmaceutical Industries Ltd.
Treatment for: Neutropenia Associated with Chemotherapy

Granix (tbo-filgrastim) is a leukocyte growth factor indicated for the reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.

Read more: Granix (tbo-filgrastim) FDA Approval History

Linzess (linaclotide) Capsules

Date of Approval: August 30, 2012
Company: Allergan, Inc.
Treatment for: Irritable Bowel Syndrome, Constipation -- Chronic

Linzess (linaclotide) is a guanylate cyclase-C agonist indicated in adults for treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

Read more: Linzess (linaclotide) FDA Approval History

Xtandi (enzalutamide) Capsules

Date of Approval: August 31, 2012
Company: Astellas Pharma Inc.
Treatment for: Prostate Cancer

Xtandi (enzalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with castration-resistant prostate cancer.

Read more: Xtandi (enzalutamide) FDA Approval History

New Drug Approvals Archive

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.